Mounjaro's sales dip: How cheap generics are redrawing India's GLP-1 market The arrival of cheaper semaglutide alternatives signals that the Indian obesity drug market has moved from a launch-led boom into something more structurally competitive Eli Lilly's Mounjaro posted its first monthly sales drop in India in Marcha Rs 20-crore decline, from roughly Rs 135 crore in February to Rs 114 crorejust days after a clutch of Indian generics entered the country's booming GLP-1 market
In 2024, Medicare stopped excluding Wegovy from coverage to treat obesity, which occurs along with cardiovascular disease
Here are the most common protocols: 16:8 (time-restricted eating)
Inositol: This nutrient metabolizes fats and cholesterol and aids in transporting fat in the blood stream
dependence on third party manufacturers, distributors and service providers for Ascendis products and product candidates
Understanding what these symptoms feel like can help you know what to expect, how to manage them, and when they might be more serious